Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Evaluation of tislellimab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab regimen in patients with liver metastases from colorectal cancer Rate and R0 resection rate and safety.
Colorectal Cancer|Liver Metastases
DRUG: Experimental drug
Conversion rates, Conversion rates based on RECIST1.1, 3 months|R0 resection rate, R0 resection rate based on RECIST1.1, 3 months|Drug Safety, Drug safety assessed by CTCAE v4.0; Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\], 12 months
ORR, objective response rate based on RECIST1.1, 3 months|PFS, Progression-Free Survival %, through study completion，an average of 2 years|OS, Overall survival %, through study completion，an average of 3 years|DCR, Disease control rate % based on RECIST1.1, through study completion，an average of 2 years
Evaluation of tislellimab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab regimen in patients with liver metastases from colorectal cancer Rate and R0 resection rate and safety.